Indirect comparison of anti-TNF-α agents for active ankylosing spondylitis: Mixed treatment comparison of randomised controlled trials

Clinical and Experimental Rheumatology

Volumn 31, Issue 5, 2013, Pages 717-722

  Shu, Tao ^a   Rong, Limin ^a   Feng, Feng ^a   Yang, Bu ^a   Chen, Ruiqiang ^a   Chen, GuiHua ^a   Wang, Juan ^b  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b Department of Gynaecology   (China)

Author keywords

Ankylosing spondylitis; Bayesian multiple treatment analysis

Indexed keywords

ADALIMUMAB; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; PLACEBO;

ANKYLOSING SPONDYLITIS; ARTICLE; BAYESIAN LEARNING; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; HUMAN; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELIABILITY; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; VALIDITY;

ADULT; ANTI-INFLAMMATORY AGENTS; BAYES THEOREM; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; MALE; MARKOV CHAINS; MONTE CARLO METHOD; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SPONDYLITIS, ANKYLOSING; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84884965874     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. FELDTKELLER E, KHAN MA, van der HEIJDE D, van der LINDEN S, BRAUN J: Age at disease onset and diagnosis delay in HLAB27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int 2003; 23: 61-6.
2. WARD MM: Functional disability predicts total costs in patients with ankylosing spondylitis. Arthritis Rheum 2002; 46: 223-31.
3. BOONEN A, van der HEIJDE D, LANDEWé R, et al: Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis 2002; 61: 429-37.
4. ZOCHLING J, van der HEIJDE D, BURGOSVARGAS R, et al: ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006; 65: 442- 52.
5. TOUSSIROT E, LAFFORGUE P, BOUCRAUT J, et al: Serum levels of interleukin 1-beta, tumor necrosis factor-alpha, soluble interleukin 2 receptor and soluble CD8 in seronegative spondylarthropathies. Rheumatol Int 1994; 13: 175-80.
6. GROM AA, MURRAY KJ, LUYRINK L, et al: Patterns of expression of tumor necrosis factor alpha, tumor necrosis factor beta, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy. Arthritis Rheum 1996; 39: 1703-10.
7. BRAUN J, BOLLOW M, NEURE L, et al: Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995; 38: 499-505.
8. BRAUN J, BRANDT J, LISTING J, et al: Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359: 1187-93.
9. GORMAN JD, SACK KE, DAVIS JC Jr: Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002; 346: 1349-56.
10. BRANDT J, KHARIOUZOV A, LISTING J, et al: Six-month results of a double-blind, placebo- controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003; 48: 1667-75.
11. DAVIS JC, Jr., Van Der HEIJDE D, BRAUN J, et al: Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003; 48: 3230-6.
12. CALIN A, DIJKMANS BA, EMERY P, et al: Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004; 63: 1594- 600.
13. MARZO-ORTEGA H, McGONAGLE D, JARRETT S, et al: Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. Ann Rheum Dis 2005; 64: 1568-75.
14. van der HEIJDE D, DIJKMANS B, GEUSENS P, et al: Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005; 52: 582-91.
15. van der HEIJDE D, Da SILVA JC, DOUGADOS M, et al: Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. Ann Rheum Dis 2006; 65: 1572-7.
16. van der HEIJDE D, KIVITZ A, SCHIFF MH, et al: Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006; 54: 2136-46.
17. INMAN RD, DAVIS JC, JR., HEIJDE DV, et al: Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008; 58: 3402-12.
18. INMAN RD, MAKSYMOWYCH WP, CANDLE STUDY GROUP: A double-blind, placebocontrolled trial of low dose infliximab in ankylosing spondylitis. J Rheumatol 2010; 37: 1203-10.
19. DOUGADOS M, BRAUN J, SZANTO S, et al: Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE). Ann Rheum Dis 2011; 70: 799-804.
20. HUANG F, ZHANG J, ZHENG Y, et al: [A multicenter, double-blind, randomized, placebocontrolled clinical trial of etanercept treatment of Chinese patients with active ankylosing spondylitis]. Zhonghua Nei Ke Za Zhi 2011; 50: 1043-7.
21. NAVARRO-SARABIA F, FERNÁNDEZ-SUEIRO JL, TORRE-ALONSO JC, et al: High-dose etanercept in ankylosing spondylitis: results of a 12-week randomized, double blind, controlled multicentre study (LOADET study). Rheumatology (Oxford) 2011; 50: 1828-37.
22. MOHER D, LIBERATI A, TETZLAFF J, ALTMAN DG, and the PRISMA GROUP: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.
23. LIBERATI A, ALTMAN DG, TETZLAFF J, et al: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009; 62: e1-34.
24. DIAS S, WELTON NJ, SUTTON AJ, et al: NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials. 2011; last updated April 2012; available from http://www. nicedsu.org.uk
25. LU G, ADES AE: Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004; 23: 3105-24.
26. CALDWELL DM, ADES AE, HIGGINS JP: Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005; 331: 897-900.
27. SPIEGELHALTER D, THOMAS A, BEST N, et al: WinBUGS user manual version 1.4. 2003; available from http://www.mrc-bsu. cam.ac.uk/bugs/ (accessed 2007).
28. SIEPER J: Developments in therapies for spondyloarthritis. Nat Rev Rheumatol 2012; 8: 280-7.